Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data

Novo Nordisk A/S’ (NYSE:NVO) stock is trading higher on Friday as the Wegovy (semaglutide) pill hit 3,071 U.S. prescriptions in the first four days after its launch, Reuters noted, citing IQVIA data.Performance DataWegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.The weight loss pill was approved in December 2025.The market ‍is closely watching early sales ...